Compare Abeona Therapeutics Inc (ABEO) vs Allstate Corp (ALL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Allstate Corp — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Allstate Corp trades at $252.24 (market cap $63.94B). The key difference: Allstate Corp is far larger — about 171.3× Abeona Therapeutics Inc's market cap, and Allstate Corp pays a 1.74% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ALL | |
|---|---|---|
Market Cap | $373.32M | $63.94B |
Sector | Health | Financials |
52-Week High | $7.23 | $251.46 |
52-Week Low | $4.17 | $190.00 |
Enterprise Value | $228.22M | $72.73B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Allstate (ALL) trades at $251.46, up 0.45% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 5.49, net income margin of 17.98%, and consistent earnings beats in recent quarters. Recent news highlights Q2 2026 earnings anticipation and dividend declarations, reinforcing positive sentiment.
Outlook remains favorable given valuation discounts and earnings strength, though risks include potential hurricane impacts and market volatility. Analyst consensus leans bullish with a $249.50 price target, suggesting near-term stability with upside potential from continued operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →
